Fundraising FoxTympanogen
Richmond, US · 2 known investors
Find your way into Tympanogen
Each arrow is one introduction. Sign up to fill in the first one.
Ask Leen Kawas to introduce you to Elaine Horn-Ranney
You →Leen · together at Tympanogen →Elaine
Sign up to find every way you can get introduced to Tympanogen
- Your email: who you already know at Tympanogen, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Tympanogen team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
Founders & leadership
Investors · 2
How we know: Citrine Angels's portfolio page · Not right? Tell us
How we know: press coverage · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 3 rounds · 2021–2025
▶$1.2MraisedMar 2025 · 33 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $1.2M
- Minimum investment
- $10K
- First sale
- Feb 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$25KraisedMay 2023 · 1 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $1M
- Amount sold
- $25K
- Minimum investment
- $25K
- First sale
- Apr 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1MraisedMar 2022 · 12 investors · Other TechnologyRule 506(b)
- Elaine Horn-RanneyExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $1M
- Minimum investment
- $20K
- First sale
- Oct 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2023 | $3.2M |
| Department of DefenseDefense Health Program | Phase I | 2020 | $250K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $1.5M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Tympanogen do?
- Tympanogen develops Perf-Fix, a gel patch system for nonsurgical eardrum (tympanic membrane) repair that replaces traditional tympanoplasty with a clinic-based procedure. The product is aimed at ENT surgeons and clinicians for outpatient otologic care and is currently in development.
- Who founded Tympanogen?
- Tympanogen was founded by Elaine Horn-Ranney.
- Who are Tympanogen's investors?
- Tympanogen's investors include Citrine Angels, Virginia Venture Partners.
- How much funding has Tympanogen raised?
- Tympanogen has disclosed $2.2M raised across 3 rounds.
- Where is Tympanogen headquartered?
- Tympanogen is headquartered in Richmond, US.